Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research
European Journal of Neuroscience · 2026-10 · 64 (8)
DOI: 10.1111/ejn.70718 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, online erschienen am 21.10.2026. Verfasst von S Mohana Lakshmi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Pharmacy, Amity University Bengaluru, Bengaluru, Karnataka, India. Hauptthemen laut MEDLINE: Microglia, Neuroinflammatory Diseases, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit nennt 239 Literaturangaben.
Abstract (Originalsprache)
Microglia are the immune cells resident in the central nervous system (CNS) and are involved in CNS homeostasis and in responses to injury and disease. Microglia, upon activation, become pro‐inflammatory (M1) or anti‐inflammatory (M2), with M1 being neurotoxic and M2 participating in tissue repair. The activation of microglia in neuroinflammation and pain hypersensitivity is important in the neurodegenerative disorders such as Parkinson's (PD) and Alzheimer's disease ( AD ). Recent investigations have identified GLP‐1 receptor agonists (GLP‐1 RAs) as potent pharmacological agents that can regulate the activity of the microglia. GLP‐1RA attaches to the GLP‐1 receptor found on the microglia to cause a phenotypic shift to the anti‐inflammatory M2 form, which, in turn, reduces neuroinflammation and increases neuronal protection. Experimental evidence shows that GLP‐1 RAs are effective at reducing hypersensitivity to pain, improving cognitive performance, and attenuating inflammatory effects in preclinical models of AD , PD, and multiple sclerosis (MS). All these facts suggest that GLP‐1 RAs are a significant treatment option in chronic pain and neurodegenerative disease management, as they can change microglial polarization and suppress neuroinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Amity Institute of Pharmacy, Amity University Bengaluru, Bengaluru, Karnataka, India.
- Department of Medical Laboratory Technology, School of Allied Health Sciences, Galgotias University, Greater Noida, Gautam Buddha Nagar, Uttar Pradesh, India.
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India.
- Department of Pharmacology, Yenepoya Pharmacy College and Research Centre, Yenepoya (Deemed to be) University, Mangalore, India.
- Department of Pharmaceutical Technology, Bharat Technology, Uluberia, West Bengal, India.
- Department of Pharmaceutics, SRM College of Pharmacy, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
ORCID-Profile: S Mohana Lakshmi, Vijay Singh, Murugesan Vanangamudi, Tahreen Taj, Haleema Shahin Dh, Rajarshi Nath, Gouranga Dutta, Uttam Prasad Panigrahy, Nadira Noushida, Priya Chaudhary
Zitieren
APA
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin Dh, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., Noushida, N., & Chaudhary, P. (2026). Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research. European Journal of Neuroscience, 64(8). https://doi.org/10.1111/ejn.70718
Vancouver
Lakshmi SM, Singh V, Vanangamudi M, Taj T, Shahin Dh H, Nath R, et al. Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research. European Journal of Neuroscience. 2026;64(8). doi:10.1111/ejn.70718
BibTeX
@article{Lakshmi2026,
author = {Lakshmi, S Mohana and Singh, Vijay and Vanangamudi, Murugesan and Taj, Tahreen and Shahin Dh, Haleema and Nath, Rajarshi and Dutta, Gouranga and Avvari, Sanjeeva Kumar and Sridhar, Sathvik Belagodu and Panigrahy, Uttam Prasad and Noushida, Nadira and Chaudhary, Priya},
title = {Modulating Microglial Activation Through GLP‐1 Pathways: A New Frontier in Neuroinflammation Research},
journal = {European Journal of Neuroscience},
year = {2026},
volume = {64},
number = {8},
doi = {10.1111/ejn.70718}
}
EUVIMED